University Medical Center Mainz, Department of Radiotherapy Trials

University Medical Center Mainz, Department of Radiotherapy	Welcome, Profile Billing Logout

University Medical Center Mainz, Department of Radiotherapy

Welcome, Profile Billing Logout

2 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Schmidberger, Heinz

RADIANCE, NCT04230759 / 2018-003005-25: Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. a Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group

Active, not recruiting

180

Europe

Chemotherapy, all brands of 5-fluorouracil (5-FU) are allowed, all brands of Mitomycin C (MMC) are allowed, Radiation, Durvalumab, PD-L1 inhibitor

Goethe University, German Cancer Aid, AstraZeneca

Anal Cancer, Anal Carcinoma, Anal Cancer Stage III, Anal Cancer Stage II

12/26

03/27

DELPHI, NCT03396718: De-escalation of Adjuvant Radio (chemo) Therapy for HPV-positive Head-neck Squamous Cell Carcinomas

Recruiting

N/A

304

Europe

De-escalation radio(chemo)therapy - Level 1, De-escalation radio(chemo)therapy - Level 2, Standard radio(chemotherapy)

Technische Universität Dresden, German Cancer Research Center, National Center for Tumor Diseases (NCT) Dresden, National Center for Tumor Diseases, Heidelberg, Radiation Oncology Working Group of the German Cancer Society

Head-and-neck Squamous Cell Carcinoma

11/29

11/32

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites